Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health to Present Data on TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
WALTHAM, Mass. , March 18, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it
View HTML
Toggle Summary Radius Health to Present at Cowen 39th Annual Healthcare Conference
WALTHAM, Mass. , March 11, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Cowen 39 th Annual Healthcare Conference on Wednesday, March 13, 2019 .
View HTML
Toggle Summary Radius Health to Participate in 2019 Credit Suisse Global Healthcare Conference
WALTHAM, Mass. , March 01, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Company management will be attending and participating in the 2019 Credit Suisse Global Healthcare Conference in London on Tuesday, March 5, 2019 and hosting one-on-one meetings with
View HTML
Toggle Summary Radius Health Announces Fourth Quarter and Full-Year 2018 Operating Results
TYMLOS® U.S. net sales continued to increase, reaching $34.4 million in the fourth quarter of 2018  and totaling $99.2 million for full-year 2018, exceeding the Company’s guidance of $95-98 million . Elacestrant’s Phase 3 study was initiated at the end of 2018 and is open for enrollment.
View HTML
Toggle Summary Radius Health to Present at Leerink Partners 8th Annual Global Healthcare Conference
WALTHAM, Mass. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Leerink Partners 8 th Annual Global Healthcare Conference on Friday, March 1, 2019 .
View HTML
Toggle Summary Radius Health to Announce Fourth Quarter and Full Year 2018 Financial Results, Host Conference Call and Live Webcast on Thursday, February 28, 2019
WALTHAM, Mass. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019 . The Company will host a conference call and live audio webcast at 4:30 p.m.
View HTML
Toggle Summary Radius Health Appoints Jessica Hopfield, Ph.D., to Board of Directors
WALTHAM, Mass. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and
View HTML
Toggle Summary Radius Exceeds 2018 Financial Guidance and Provides Business Update at the 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it has exceeded its 2018 financial guidance with full-year TYMLOS® U.S. net sales surpassing the upper range of $95 to $98 million . Radius closed 2018 with a $235 million cash, cash
View HTML
Toggle Summary Radius Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that President and Chief Executive Officer, Jesper Høiland , will present a corporate update at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 1:30 pm PST at the
View HTML
Toggle Summary Radius Health Provides Updates on its Oncology Programs and Announces Scientific Presentations at 2018 San Antonio Breast Cancer Symposium (SABCS)
Phase 3 elacestrant study has opened for enrollment Fast Track designation from the FDA for the Phase 3 study population Elacestrant pre-clinical data demonstrates further evidence of anti-tumor activity in breast cancer models with resistance to CDK 4/6 inhibitors and ESR1 mutations RAD140 Phase 1
View HTML